Skip to content


BMC Biotechnology

Open Access

Efficient CPP-mediated Cre protein delivery to developing and adult CNS tissues

BMC Biotechnology20099:40

Received: 14 November 2008

Accepted: 24 April 2009

Published: 24 April 2009



Understanding and manipulating gene function in physiological conditions is a major objective for both fundamental and applied research. In contrast to other experimental settings, which use either purely genetic or gene delivery (viral or non-viral) strategies, we report here a strategy based on direct protein delivery to central nervous system (CNS) tissues. We fused Cre recombinase with cell-penetrating peptides and analyzed the intracellular biological activity of the resulting chimerical proteins when delivered into cells endowed with Cre-mediated reporter gene expression.


We show that active Cre enzymatic conjugates are readily internalized and exert their enzymatic activity in the nucleus of adherent cultured cells. We then evaluated this strategy in organotypic cultures of neural tissue explants derived from reporter mice carrying reporter "floxed" alleles. The efficacy of two protocols was compared on explants, either by direct addition of an overlying drop of protein conjugate or by implantation of conjugate-coated beads. In both cases, delivery of Cre recombinase resulted in genomic recombination that, with the bead protocol, was restricted to discrete areas of embryonic and adult neural tissues. Furthermore, delivery to adult brain tissue resulted in the transduction of mature postmitotic populations of neurons.


We provide tools for the spatially restricted genetic modification of cells in explant culture. This strategy allows to study lineage, migration, differentiation and death of neural cells. As a proof-of-concept applied to CNS tissue, direct delivery of Cre recombinase enabled the selective elimination of an interneuron subpopulation of the spinal cord, thereby providing a model to study early events of neurodegenerative processes. Thus our work opens new perspectives for both fundamental and applied cell targeting protocols using proteic cargoes which need to retain full bioactivity upon internalisation, as illustrated here with the oligomeric Cre recombinase.


Nuclear Localization SignalCentral Nervous System TissueAdult Central Nervous SystemRecombination ActivityReporter Cell Line


From focal demyelination or axonal degeneration events characterizing peripheral neuropathies, to localized genetic alterations involved in primary neuro-oncogenic processes, understanding cell- and domain-specific gene function in the CNS [14] often requires the modification of gene expression in restricted cell populations. Cre-mediated recombination has become a key strategy for the spatial and temporal control of gene inactivation or over-expression. This has been mainly achieved through genetic approaches, by crossing transgenic mouse strains carrying loxP-flanked ("floxed") genes with transgenic mice expressing the Cre recombinase under the control of specific promoters, or through viral or non-viral delivery of Cre encoding DNA. With the latter strategy, spatial restriction of the infected tissue to defined areas remains challenging. As an alternative strategy, direct delivery of therapeutic agents into cells ('transduction'), has had numerous and encouraging attempts [510]. Endogenous peptides endowed with internalisation properties (Cell Penetrating-Peptides, hereafter termed "CPPs") have strongly improved the efficiency of delivery [11]. Fragments of TAT [10, 12], FGF [13], and homeoproteins are efficient peptidic vectors, which do not have obvious deleterious impact on cell survival; they have been combined, either chemically or genetically, with different macromolecular cargoes [59]. However, the restricted delivery of such compounds in topographically focalized territories has not been directly evaluated in the case of neural cells, which are highly heterogeneous in term of spatial identity. We have addressed this issue with the intra-cellular delivery of Cre recombinase fused to CPPs, a strategy which has been already well described [1318]. Cre recombinase is a large hydrophilic enzyme frequently used to perform targeted genomic recombination [19], resulting in permanent reporter transgene expression when using dedicated genetic backgrounds. This functional read-out unambiguously ensures the presence of a biologically active Cre protein inside the nucleus, contrasting with the visualisation of protein internalization that has lead to conflicting results [2025]. We show the efficient delivery of the active enzyme in topologically restricted cell populations and provide several examples of the applications of this technology to neuronal targeting and cancer research, a strategy which obviates the need for sustained expression of Cre recombinase [2629] through genetic procedures.


Fusion to Penetratin-based CPPs preserves recombinase activity and promotes nuclear Cre internalization

Cre recombinase coding sequence was genetically inserted in frame with several peptidic coding sequences coding for CPPs and the recombinant proteins were purified from bacteria (Fig. 1A & Additional file 1A). Enzymatic activity was monitored in cell-free conditions, through recombination of a target linear plasmid harbouring two loxP sites. All fusion proteins displayed similar specific recombination activities, in the range of 4 units/μg – except for Tat-Cre, which was significantly more active (16 units/μg), outperforming a commercial Cre (NEB #MO298, 11 units/μg; see Additional file 1B). As both the nuclear localization signal (NLS) and the highly basic character of the Tat and Penetratin sequences might have enhanced Cre biological activity by increasing its nuclear accumulation, independently of the internalization process [30, 31], the recombination activities of histidine-tagged Cre conjugates (HC, hNC and H3C) were further evaluated by transient transfection. The three coding sequences, sub-cloned into a mammalian expression plasmid, were expressed in CV1B cells, which display β-Galactosidase reporter activity upon Cre-mediated recombination [32]. Cre immunodetection indicated that all proteins displayed similar expression and nuclear accumulation levels (see Additional file 2A–C). Furthermore, detection of reporter activity showed similar target recombination efficiency for all tested Cre conjugates, consistent with previous observations [30, 31]. This efficacy further applied to the Antp secretion signal-appended Penetratin conjugates (H23C and H23NC), suggesting a robust nuclear targeting by the Penetratin moiety [33]. These results rule out nuclear addressing as a limiting step in Cre nuclear activity during protein transduction assays – which thus allows correlating their transduction efficiencies with the internalization step.
Figure 1

Genomic recombination upon transduction of CPP-Cre conjugates in reporter cells. (A) Peptidic additions to Cre recombinase: 'NLS', nuclear localization signal; '3' or 'Penetratin', Antennapedia transduction domain, see [5]; '23' or 'SEC', Antennapedia secretion signal, see [33]; 'TAT', transduction domain from HIV Tat protein (see [10]); 'myc', myc tag; 'his', polyhistidine tag. See also Additional file 1. (B) β-Galactosidase activity (arrow) of CV-1B reporter cells following 1 h incubation with H3C. Arrows, pairs of daughter cells from individually transduced cells. (C) Bradford quantification of total protein content after conjugate exposure showed unaffected cellular survival upon transduction. MTT cell viability assays on the same samples indicated that conjugate doses only above 5 μM were cytotoxic (not shown). (D) Dose-dependent transduction assay. Reporter activity was quantified 48 h after 1 h exposure to conjugates. The indicated proteins showed strongest activity at 4 μM, with a maximum for H3C. H3NC reached similar levels (see Additional file 2D). Scale bar in B represents 1800 μm.

We then evaluated the biological activity of these proteins upon transduction of the adherent CV1B reporter cell line [32]. Fusion of HC to Tat, NLS or Penetratin, resulted in equivalent recombination efficiency and cell survival (Fig. 1B–D) upon exposure for 60 mn. Maximal activity was obtained at 4 μM, resulting in 80% of β-Galactosidase positive cells (Fig. 1D). By contrast, the native HC protein displayed a low but significant transduction rate, with less than 20% of reporter-expressing cells. Interestingly, as previously reported, the transduction efficiency of NLS, which is not considered as a bona fide CPP, was twice that of Cre alone [32]. The simultaneous addition of both NLS and Penetratin sequences to Cre protein (H3NC) only slightly enhanced the transduction efficiency compared to H3C (see Additional file 2D). Reducing the exposure of cells to H3NC (4 μM) from 60 down to 15 mn resulted in recombination efficiency levels close to maximum (see Additional file 2E), suggesting a fast interaction of the protein with the cell surface.

CPP-Cre fusion proteins as a new tool for the study of neural development

We next addressed whether CPP-Cre mediated recombination would be suitable for the study of neural tissue. In preliminary experiments we had observed that primary neuronal cell cultures were readily amenable to transduction (data not shown). To gain further insight into the efficiency of transduction at the tissular level, we developed transduction assays on explants [3436] of adult or embryonic CNS regions derived from Cre-inducible reporter transgenic mice. The explants were cultured in serum-free medium and subsequently exposed to CPP-Cre fusion proteins (see Additional file 3). Tissue fragments were overlaid with a 1 μl drop of protein solution (10 to 400 ng/μl) and assayed for reporter activity, 1 up to 10 days later. None of the explants from reporter strains used in this study displayed recombination events upon exposure to vehicle solution (see Additional file 4). Firstly, drops of CPP-Cre were applied at the centre of telencephalic explants from E12.5–E16.5 mouse embryos (Fig. 2 and Additional file 5). Dose-response assays showed that exposure to most of these conjugates resulted in a steep response, with no or barely detectable recombination events below 100 ng/μl, and maximal reporter expression from 200 ng/μl with all tested transgenic reporter strains (see Additional files 5 and 6). Since all tested CPP or NLS conjugates induced recombination with similar efficiencies, only tissues exposed to H3NC were hereafter used to illustrate representative assays in Fig. 2, 3 and 4. As documented in Fig. 2A, B, reporter-expressing cells from R26R-derived explants were detected throughout the explant from the 200 ng/μl concentration on (see also Additional file 6). In contrast, conjugate titres below this limit resulted in restricted clusters of targeted cells (see Additional file 6). Within live cortical explants from transgenic mice carrying fluorescent inducible reporters, gene expression was detected as soon as eight hours after transduction by direct fluorescence (Fig. 2C). Indirect immunodetection and confocal analysis (Fig. 2D–G) performed 72 h later suggested that neurons might be preferential targets for CPP-Cre internalization, based on the morphology of the expressing cells (Fig. 2D, E) – consistent with previous observations [37].
Figure 2

CNS explants from Cre-dependent transgenic embryos displayed reporter activity upon exposure to CPP-Cre fusion proteins. Telencephalic explants of dissected fragments from the embryonic brain (see Additional file 3), were obtained and cultured as previously described, then exposed to protein conjugates added at the center of the explant (asterisk). Two to ten days later, transgene-expressing cells (arrows) were detected by reporter enzymatic activity (A, B), intrinsic fluorescence (C), or immunohistochemistry (D-E). Vehicle-treated explants were devoid of reporter expressing cells (see Additional file 4). (A, B) Explants (R26R strain) exposed for 96 h to a 1 μl drop of 100 ng/μl H3NC. Visualization of reporter activity (X-gal staining; positive blue cells indicated by arrows) showed reporter-expressing cells, located mainly in the peripheral domain (B). (C) Explant from RYFP strain, exposed for 8 h to a 1 μl drop of 100 ng/μl H3NC. Live fluorescence recording (GFP channel; bright green cells, arrow) shows early recombinant cells in the centre of the explant. (D-E), YFP immunofluorescence analysis using a pan-GFP antibody revealed reporter expression in large cell clusters, 72 h after H3NC transduction (1 μl drop of 100 ng/μl). In (D), labelled cells were classically documented while in (E), reporter YFP was analysed using confocal analysis (pseudo-colors GLOW-LUT converted representing signal intensity, blue indicating saturated signal). In A-E, arrows point to representative recombinant cells, including those with a morphology suggestive of neuronal identity in pictures D-E. For the whole figure, the scale bar in A represents: A, 350 μm; B, 750 μm; C, 150 μm; D, 50 μm; E, 1000 μm.

Figure 3

Focal recombination obtained through genetic and mechanical approaches. (A, B) Genetic approach. Conditional induction of a caspase-dependent pro-apoptotic program in a neuronal subpopulation. Flat-mount embryonic spinal cord explants, from wild-type (A) or Dbx1-DTA strain (B), exposed for 96 h to 1 μl of 400 ng/μl H3NC. Activated-caspase III immunodetection showed induction of early steps of apoptosis only in transgenic explants exposed to the conjugate (B; arrows: representative positive cells, purple staining). The apoptotic marker was not induced in non-transgenic tissue (A). Likewise, vehicle solution did not induce significant apoptosis (see Additional file 4C). Red double arrow: floorplate (see also Additional file 3). (C-F) Mechanical approach. Focal conjugate delivery produced clusters of recombined cells. (C) H3NC-soaked beads (200 ng/μl) were deposited onto Z/AP cortical explants. hPLAP reporter activity was monitored 24 h later (purple precipitate). Inset, clusters of radiating positive cells. (D) In contrast, the drop assay using the same protein solution (200 ng/μl) on parallel explants led to widely dispersed reporter-expressing cells (inset, higher magnification). (E-F) Combination of genetic and focalized restriction of cell targeting. Detection of simultaneous reporters (β-Galactosidase, blue; GFP, brown; arrow) induced by H3NC (200 ng/μl) in TGZ cortical explants. In both C (top cluster of positive cells, asterisk) and F explants (center, asterisk), one bead was removed, exposing cells in contact with the beads. Arrows (E, F): representative nuclei surrounded by dense axon bundles, suggestive of neurons. For the whole figure, scale bar in A represents: A, B, E, 300 μm; C, D, 1000 μm; F, 150 μm.

Figure 4

Adult tissues are amenable to topographically restricted cell targeting. (A-C) Adult forebrain slice explants (R26R strain), exposed to a 1 μl drop of 100 ng/μl H3NC, displayed reporter β-Galactosidase activity (blue staining, arrows) throughout brain regions. Boxed area in A is observed at higher magnification in B. Dashed lines in B encompass periventricular layers. (C), higher magnification in the striatum. The arrow points to representative recombinant cells arranged as glomerula. (D) Fragment of adult cerebellum explants (TGZ strain) exposed to H3NC (100 ng/μl), displayed reporter alkaline phosphatase immunopositive cells, most of which appear arranged in a laminar organization suggestive of Purkinje cell layer. The arrowheads point to representative recombinant cells within the Purkinje cell layer, while the arrows indicate rare positive cells outside of it. For the whole figure, the scale bar in A represents: A, 1600 μm; B, 800 μm; C, 130 μm; D, 3000 μm.

Although indicative of efficient recombination, the drop delivery approach resulted in a heterogeneous distribution of reporter-expressing cells, either at the centre or at the periphery of the explant, which could reflect the persistent drift of the proteins towards the edge of the explants. We thus examined whether recombination could be further restricted to cell subpopulations of the developing CNS thanks to the use of lineage-specific promoters. For this purpose we targeted a single lineage of neuroblasts in a model of neuronal apoptosis. The fusion proteins were used to transduce E9.5–E14.5 spinal cord explants from the Dbx1-Dta strain (kindly provided by Dr A. Pierani [38, 39]), in which only Dbx1-positive interneurons express the pro-apoptotic diphtheria toxin A fragment. Apoptosis can then be evidenced by induction of activated caspase III. Upon transduction, apoptotic cells could be detected only within transgenic explants exposed to Cre fusion proteins (Fig. 3B) but not with vehicle solution (see Additional file 4). These cells were arranged along two parasagittal lines, consistent with the distribution of Dbx1 positive interneurons (A. Pierani, personal communication). In contrast, fusion proteins did not induce significant apoptosis in non-transgenic explant (Fig. 3A). Expression of the target transgene, performed here to monitor early events during cell death, can thus be induced in a lineage-restricted population, depending upon the activity of its promoter. Furthermore, these observations underline the innocuous character of the exposure to CPP-Cre conjugates, as illustrated by the absence of significant apoptosis in Dbx1 negative cells.

Next we asked whether topologically restricted recombination could be obtained using ubiquitously expressed instead of cell-type restricted reporter transgenes. To spatially restrict recombination, we focused the territory of protein delivery using neutral beads soaked with CPP-Cre proteins. The beads were implanted onto embryonic brain explants derived from the Z/AP strain, in which alkaline phosphatase is expressed upon Cre-mediated recombination. As illustrated in Fig. 3C, cohorts of cells were detected only in close proximity of the beads (inset). In contrast, in a parallel drop assay using the same protein solution used for bead soaking, positive cells were widely dispersed throughout the explant surface (Fig. 3D). The limited diffusion of the fusion proteins using focal bead implantation thus allows spatial targeting of small cell clusters.

In order to verify that neuronal populations were actually transduced using this protocol, explants from the axon-specific TGZ transgenic strain were incubated with CPP-Cre soaked beads. Following incubation, numerous reporter-expressing neuronal cells characterized by β-Galactosidase positive nuclei and MARCKS-eGFP positive neurites were detected at the vicinity of the beads (Fig. 3E, F). This assay further illustrates the modularity of the system, with the restriction of reporter expressing cells by a combination of focal delivery and promoter-specific transgenic lines.

Whether cells from adult tissues would be similarly amenable to CPP-mediated transduction of Cre recombinase remained to be determined. Serial sections from adult brains of the same mouse strains were exposed to drops of CPP-Cre conjugates. A robust staining developed, delineating the laminar organization of the brain as illustrated in Fig. 4. Noticeably, all Penetratin-based conjugates displayed similar targeting efficiency with the R26R strain, such that transgene-expressing cells spanned the whole surface and thickness of all exposed explants (see Additional File 5). A higher concentration of recombinant cells could be detected in cell-dense domains such as progenitor-rich periventricular layers (Fig. 4A, B) and striatal clusters (Fig. 4A, C). Remarkably, when cerebellar slices were exposed to the drop transduction assay, the predominant reporter-expressing population was constituted by Purkinje cells (Fig. 3D; see [14]). Transduction thus also occurred in mature neurons of the adult CNS.


We recently reviewed [11] the encouraging properties of CPP-based conjugates, including their neural tropism. Efficient direct protein delivery into neural nuclei would greatly improve fundamental and clinical research in neuroscience. Here, we developed non-viral transduction assays based on organotypic cultures from transgenic mice as a surrogate model of live CNS tissue. As reported by others, including in vivo studies [8, 18, 31], we confirm that fusion proteins between CPPs and a large enzyme, the Cre recombinase, are readily translocated through cell membranes and further shuttled inside the nucleus to target genomic loci. Since successful delivery in the CNS of other kind of proteins fused to CPPs have been reported in vivo [8, 11, 40, 41], our strategy might thus be not limited to Cre conjugates.

Our study further expands the applications of this strategy to neural explant culture. High levels of recombination were reached on explants upon exposure with as few as 200 ng of protein, and transduction resulted in a mosaic of recombined and unaffected cells within live tissues. Although easy to perform and efficient, the drop approach is poorly reproducible in terms of spatial distribution, mainly because the diffusion of the protein depends on the shape of the explant. With the bead protocol, spatial restriction of recombination to defined areas can easily be achieved, depending upon the position of the bead. In the explant assays, most of the Cre conjugates displayed similar biological activity (see Additional file 5). We only noticed enhanced specific activity of Tat-Cre for cell-free DNA recombination, compared to that of Penetratin-based conjugates (4-fold) – although their cellular activities were similar. This might reveal differential properties of these two CPPs, at least in the context of fusion with Cre protein.

Direct delivery of Cre conjugates presents several advantages over viral strategies, although these latter have been successfully used. In addition to the technical and safety limitations inherent to the production of viruses [42, 43], viral-mediated Cre delivery results in the prolonged expression of the enzyme, with possible adverse effects [16, 27]. With our approach, we did not observe a dramatic increase in the number of recombinant cells between 8 h and 96 h following treatment (compare Fig 3C, and 3D–E), suggesting the temporal restriction of the recombination events to the first hours of incubation. Indeed, a similar situation is observed in cell culture, where optimal recombination activity is almost reached after a 15 mn exposure to Cre conjugates (see Additional file 2E). Among credible possibilities, the limited stability of the protein in the extracellular medium might account for this observation. This strategy might be used in a pulse application for selecting Cre-dependent genomic constructs or removing undesirable entities from manipulated stem cells, as performed in [16, 18].

On cerebral explants, neurons were prime targets for transduction, both upon generalized (drop) and focalized (bead) delivery. In terms of ontogenesis, we and others previously showed that regionalized properties develop early during mouse CNS formation [4446], resulting from the combined activities of recently identified genetic programs. Which mechanisms underlie neurogenesis might be best understood through focal manipulation of gene function in defined territories. Interestingly, the function of both proliferating and mature post-mitotic neurons of the adult brain can also be approached with this strategy, although the efficiency of the transduction seems decreased.

In adult cerebellar explants, the preferential restriction of recombination events to Purkinje neurons was unexpected and might rely on their larger membrane area offered by their extensive dendritic arborization tree. Whichever mechanism is involved, targeting of this cell type – the largest cell and sole axonal output to extra-cerebellar targets – would be a decisive asset to understand normal and pathologic events during the formation and function of the cerebellum. Peptide-mediated non-viral transfer of proteic cargoes could thus offer a valuable alternative strategy to viral-mediated gene transfer using Purkinje cell-specific targeting elements [29], with the advantage of a non-toxic and rapidly cleared vector [27].


Controlled inactivation or over-expression of genes both at the spatial and temporal level has become a key strategy in the study of gene function. Our study provides an alternative and complementary strategy to the use of Cre expressing mouse strains or of viral-mediated delivery that can be applied to both explant culture and in vivo models. The originality of this strategy relies on the spatial and temporal restriction of recombinant cells without the need of specific promoters. We demonstrate that this method of transduction could find innovative applications in different areas of neuroscience including neural development and neurophysiology.


Expression vectors of CPP-Cre fusion proteins

Plasmids were derived from pTHCremyc and pTHnlsCremyc constructs harboring a T7 polymerase promoter. CPP sequences were inserted in frame by oligonucleotide insertion in the unique restriction sites SpeÉ and KpnÉ localized between polyhistidine and Cre recombinase coding sequences (see Additional file 1). Eukaryotic expression plasmids used in this work were designed by subcloning of the sequences encoding for CPPs-Cre-myc (without His tag) derived from pTH vectors into pTL plasmids (pSG5 derivative), in which the expression is under control of a viral SV40 promoter. All plasmid sequences were verified by sequencing. HisCreTAT expression plasmid [10] was kindly provided by Dr S.F. Dowdy (UCSD, La Jolla, CA, USA).

Expression and purification of recombinant fusion proteins

pTH plasmids encoding different CPPs-Cre fusion proteins were used to transform the E. coli strain BL21(DE3)pLysS (Novagen), allowing isopropyl β-D-thiogalactoside (IPTG)-inducible expression of His-tagged proteins. An enriched medium of Luria Broth/2%glucose containing 50 μg/ml ampicillin and 34 μg/ml chloramphenicol was used for overnight preculture. 500 ml cultures of LB at 50 μg/ml ampicillin and 0.5% glucose were then inoculated by 1:20 dilution of preculture and grown at 37°C until OD(600 nm) reached 0.4. Protein overexpression was induced by 1 mM IPTG for 3 hours at 28°C. Cells were harvested by centrifugation and pellets were frozen dry at -80°C for storage. Cell pellets were resuspended in lysis buffer (500 mM NaCl, 25 mM Hepes, 5 mM imidazole, 5 mM MgCl2, 50 μg/ml DNAse, 2 μg/ml RNAse, and proteases inhibitors; Invitrogen) in a final volume of 10 ml. Cleared lysates were obtained by French press bacterial disruption and subsequent centrifugation for 1 hour at 12000 g at 4°C. After 0.45 μm filtration, the supernatant was loaded onto Histrap Ni2+ affinity column (Amersham) and subsequently washed with 10 bed volumes of a 500 mM NaCl, 25 mM Hepes, 10 mM imidazole solution. Recombinant proteins were purified through one-step FPLC chromatography, by linear gradient-mediated elution from 10 to 500 mM imidazole. Fractions were analyzed by SDS-PAGE and those which showed the presence of purified protein were pooled (1 to 4 mg) and dialyzed overnight at 4°C in Pierce 10 K dialysis cassettes against pH 5 dialysis buffer (20 mM Sodium Acetate pH 5, 10 mM β-mercapto-ethanol, 40 mM NaCl). After dialysis and removal of precipitated material, protein concentration was determined using Bradford assay and 12% SDS-PAGE analysis and ranges from 0.4 to 1 μg/μl (compared to 1 to 2 μg/μl before dialysis). Proteins were stored at -80°C. Glycerol cryoprotection was omitted in order to avoid possible interference with membrane permeability upon protein exposure to live cells.

Cell-free assay of CPP-Cre recombinase activity

Recombination assays were performed in 10 μl of buffer (50 mM Tris-HCl pH 7.5; 33 mM NaCl; 10 mM MgCl2) containing 250 ng of XmnÉ-linearized pLox2 plasmid (Clonetech, [47]). To compare the efficiency of recombination in vitro, a range of 100, 50, 25, 12.5 and 6.25 ng of purified Cre fusion proteins, were added, for 1/10th of the reaction volume. After 30 mn incubation at 37°C, reactions were stopped by adding 2 μl of 6× loading buffer (0.025% Bromophenol blue; 0.025% xylene cyanol; 60% glycerol; 1% SDS; 100 mM EDTA) and inactivation for 10 mn at 70°C. The reactions were then resolved on a 1.5% agarose gel. Quantification of the recombination activity was based on the comparison with a commercial Cre enzyme (NEB) and expressed according to the manufacturer unit definition.

Protein transduction: Cellular-based assays of CPP-Cre activity

Adherent CV1B fibroblasts were kindly provided by Dr F. Tronche and used as described in the original publication [32]. In this reporter cell line, a floxed neomycin resistance/poly-adenylation cassette has to be excised to allow E. coli lacZ expression. Cre recombinase activity in the nucleus thus results in β-Galactosidase activity. The cells were cultured in Dulbecco's Modified Eagles medium (DMEM)/F12 medium (Gibco) supplemented with 10% fetal calf serum (FCS), penicilline (50 U/ml), streptamycine (50 μg/ml), G418 (100 μg/ml) and DnaseI (10 μg/ml). For internalization experiments, 5000 cells/well were seeded into 96-well plates coated with 1.5 μg/ml poly-ornithine (Sigma), then washed in DMEM/F12 serum-free medium. Upon internalization, cells were incubated in presence of CPP-Cre proteins diluted in DMEM/F12 supplemented with 10 mM HEPES and 100 μg/ml bovine serum albumine (BSA). Protein solutions were prepared extra-temporaneously. After protein exposure (15 to 60 mn), cells were washed with 10% FCS medium, then re-incubated for 24 or 48 hours, and subsequently monitored for reporter β-Galactosidase activity using either CPRG assay (see below) or Xgal staining (as previously described [34, 35]).

Plasmid DNA transfection experiments

CV1 fibroblasts were grown for 24 h in 10%FCS. Lipofection of 50000 cells was carried out by adding into each 24-well a mixture of Lipofectamine (Invitrogen), 200 ng of control Alkaline Phosphatase (AP)-encoding plasmid and 200 ng of CPP-Cre encoding plasmid – all diluted in Optimem medium. After 6 h of incubation, transfection medium was substituted by 10% FCS and incubation was resumed for 24 h. Cells were washed with PBS, fixed in 2.5% glutaraldehyde for 5 mn on ice and assayed for β-Galactosidase activity by Xgal staining. AP was detected using NBT and BCiP for 30 mn at room temperature.

Enzymatic assays

To detect β-Galactosidase activity by CPRG assay, cells were washed twice with PBS, lysed in 50 μl buffer (0.1% Triton X-100, 250 mM Tris-HCl pH 8.0) frozen-thawed twice at -80°C from 37°C. 10 μl aliquots were reserved for quantitation with Bradford assay. The lysates were mixed with 150 μl of CPRG detection solution (2.5 ml CPRG substrate stock at 4 mg/ml, 35 μl β-Mercapto-ethanol 14.3 M, 7.5 ml Buffer pH 7.0 (60 mM Na2HPO4, 40 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4). After incubation for 15, 30, 60, 90, and 120 mn, OD(570 nm) was assessed using an ELISA plate reader. CPRG data obtained from the wells treated with CPPs-Cre proteins were normalized against background signals obtained with vehicle-treated cells. Bradford assay was performed according to the manufacturer's instructions (Biorad). In parallel, an aliquote of each sample was used to monitor cell viability using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cell death assay (Millipore procedure). CPRG/MTT ratios were used to quantify β-Galactosidase activity.


All immunodetections were performed as previously described [3436], using the following primary antibodies at 1/500: anti-β-Galactosidase (Cappel), anti-GFP (which recognizes all GFP-derived isoforms, including YFP; Molecular Probes), and secondary antibodies from Jackson labs at 1/200 (against rabbit and mouse IgGs) conjugated to either horseradish peroxidase or fluorescein. Anti-Cre antibody raised against a Cre fusion protein was a gift from Dr A. Prochiantz.

Cre-dependent reporter transgenic mouse strains

For most reporters in this work, the internalization of the Cre was monitored by genomic excision of a "floxed" cassette, allowing the expression of various indicator genes. The transgenic constructs contained stop or βgeo (β-Galactosidase/neomycine resistance) cassettes, flanked by two loxP sites in direct orientation. The cassette sequence is removed by excisive Cre-mediated recombination, allowing the expression of the reporter gene. Mice were genotyped using procedures from original descriptions and handled according to institutional recommendations. Excision of the underlined sequence led to the expression of the reporter moiety indicated in bold:

R26R [48]: pROSA trapped promoter – loxP – STOP – loxP – β-geo (nuclear β-Galactosidase);

RYFP [49]: pROSA trapped promoter – loxP – STOP – loxP – YFP (cytoplasmic+nuclear Yellow Fluorescent Protein);

Z/AP [50]: pCMV-pβ-actin – loxP – βgeo – loxP – hPLAP (membrane human Placental Alkaline Phosphatase);

TGZ [51, 52]: pCMV – loxP – STOP – loxP – MARCKS::eGFP-IRES-nlsLacZ (axonal Green Fluorescent Protein and nuclear β-Galactosidase);

Dbx1-DTA [38]: pDbx1loxP – STOP – loxP – DTa (Diphteric Toxin A-fragment).

Absence of leaky transgene expression and presence of proper specific reporter expression was genetically controlled using mating with Cre-driver strains (not shown). Ubiquitous reporter expression is displayed upon recombination of the R26R, RYFP and Z/AP transgenes. In contrast TGZ expression is restricted to neuronal cells, and Dbx1-Dta is specific of Dbx1+ interneurons.

Explant transduction procedure

Mice were handled according to institutional guidelines. Embryos were obtained from mating between syngenic mice, with detection of the vaginal plug considered as embryonic day 0.5 ('E0.5'). Pregnant mice were subjected to Nembutal overdose, and embryos transferred in PBS for dissection. Vitelline yolk sac fragments were used for genotyping according to original description of transgenic strains. As illustrated (see Additional file 3), fragments from several regions of the CNS including telencephalon, cerebellum and spinal cord were dissected from transgenic embryos or adults. Meninges were removed and CNS tissues were cultured on a polyester porous membrane (0.22 μm, Millipore), floating above serum-free medium (DMEM-F12 supplemented with Gibco N2 and B27 additives), as previously described [3436, 53]. They were challenged to express Cre-dependant transgenes upon exposure to the same sets of CPP-Cre fusion proteins, in individual wells. Vehicle solution and each conjugate were applied to at least two explants per series. Necrotic explants were discarded. Exposure was performed only 24 h after dissection to avoid non-specific internalization through membranes wounds due to dissection. Two modalities of exposure were used. In drop assay, a single 1 μl drop of purified protein in dialysis buffer was slowly laid onto the exposed surface of the explant, in the centre of the explant (see Additional file 3). In bead assay, neutral Affi-Gel beads (150–300 μm mesh, Biorad) were incubated with protein batches diluted to 400 ng/μl in PBS and rinsed, then deposited onto various spots of the explant surface. In contrast with cell culture, proteins or beads were not washed-out from the explants and transgene expression was monitored 1 to 14 days after treatment using dedicated procedures for the detection of β-Galactosidase protein or activity, human Placental Alkaline Phosphatase activity or fluorescent proteins.



We thank Valérie Lebled-Maité, Yann Barraud, Pierrecesare Grimaldi, Murielle Rallu and Claire Chevalier for valuable cooperation. This work was initiated in Pr. Alain Prochiantz's laboratory at the ENS (Paris), by Dr. Marie-Luz Montesinos and Pr. Michel Volovitch. We express deep appreciation to Drs. François Tronche, Sylvia Arber, Alexandra Pierani and Steven Dowdy for generous gift of cells, mice, and construct. We extend our thanks to Pr. Barbara Demeneix for critical reading of the manuscript; and Drs. Michel Cohen-Tannoudji, Marion Wassef and Valerie Mezger-Lallemand for valuable discussions. Funding was granted to AJ by EC Framework 5 (Grant #QTLK3-2002-01989; Cell-Penetratin Peptides consortium), then taken over by EC Framework 6 (Grant #LSHN-CT-2005-018652; CRESCENDO consortium) granted to GL.

Authors’ Affiliations

Evolution des Régulations Endocriniennes, CNRS UMR 7221, Muséum National d'Histoire Naturelle, Paris, France
Groupe de Biologie Cellulaire des Homéoprotéines, CNRS UMR 8542, Ecole Normale Supérieure, Paris, France
Collège de France, Ecole Normale Supérieure, CNRS UMR 8542, Paris Cedex 05, France


  1. Rakic P, Hashimoto-Torii K, Sarkisian MR: Genetic determinants of neuronal migration in the cerebral cortex. Novartis Foundation Symposium. 2007, 288: 45-53.View ArticleGoogle Scholar
  2. Lemkine GF, Goula D, Becker N, Paleari L, Levi G, Demeneix BA: Optimisation of polyethylenimine-based gene delivery to mouse brain. J Drug Target. 1999, 7 (4): 305-312.View ArticleGoogle Scholar
  3. Goula D, Remy JS, Erbacher P, Wasowicz M, Levi G, Abdallah B, Demeneix BA: Size, diffusibility and transfection performance of linear PEI/DNA complexes in the mouse central nervous system. Gene Ther. 1998, 5 (5): 712-717.View ArticleGoogle Scholar
  4. Lemkine GF, Mantero S, Migne C, Raji A, Goula D, Normandie P, Levi G, Demeneix BA: Preferential transfection of adult mouse neural stem cells and their immediate progeny in vivo with polyethylenimine. Mol Cell Neurosci. 2002, 19 (2): 165-174.View ArticleGoogle Scholar
  5. Prochiantz A: Getting hydrophilic compounds into cells: lessons from homeopeptides. Curr Opin Neurobiol. 1996, 6 (5): 629-634.View ArticleGoogle Scholar
  6. Lindgren M, Hallbrink M, Prochiantz A, Langel U: Cell-penetrating peptides. Trends Pharmacol Sci. 2000, 21 (3): 99-103.View ArticleGoogle Scholar
  7. Prochiantz A: Messenger proteins: homeoproteins, TAT and others. Curr Opin Cell Biol. 2000, 12 (4): 400-406.View ArticleGoogle Scholar
  8. Joliot A, Prochiantz A: Transduction peptides: from technology to physiology. Nat Cell Biol. 2004, 6 (3): 189-196.View ArticleGoogle Scholar
  9. Stewart KM, Horton KL, Kelley SO: Cell-penetrating peptides as delivery vehicles for biology and medicine. Org Biomol Chem. 2008, 6 (13): 2242-2255.View ArticleGoogle Scholar
  10. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF: In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 1999, 285 (5433): 1569-1572.View ArticleGoogle Scholar
  11. Joliot A, Prochiantz A: Homeoproteins as natural Penetratin cargoes with signaling properties. Adv Drug Deliv Rev. 2008, 60 (4–5): 608-613.View ArticleGoogle Scholar
  12. Cai SR, Xu G, Becker-Hapak M, Ma M, Dowdy SF, McLeod HL: The kinetics and tissue distribution of protein transduction in mice. Eur J Pharm Sci. 2006, 27 (4): 311-319.View ArticleGoogle Scholar
  13. Peitz M, Pfannkuche K, Rajewsky K, Edenhofer F: Ability of the hydrophobic FGF and basic TAT peptides to promote cellular uptake of recombinant Cre recombinase: a tool for efficient genetic engineering of mammalian genomes. Proc Natl Acad Sci USA. 2002, 99 (7): 4489-4494.View ArticleGoogle Scholar
  14. Jo D, Nashabi A, Doxsee C, Lin Q, Unutmaz D, Chen J, Ruley HE: Epigenetic regulation of gene structure and function with a cell-permeable Cre recombinase. Nat Biotechnol. 2001, 19 (10): 929-933.View ArticleGoogle Scholar
  15. Nolden L, Edenhofer F, Peitz M, Brustle O: Stem cell engineering using transducible Cre recombinase. Methods Mol Med. 2007, 140: 17-32.View ArticleGoogle Scholar
  16. Xu Y, Liu S, Yu G, Chen J, Chen J, Xu X, Wu Y, Zhang A, Dowdy SF, Cheng G: Excision of selectable genes from transgenic goat cells by a protein transducible TAT-Cre recombinase. Gene. 2008, 419 (1): 70-74.View ArticleGoogle Scholar
  17. Hashimoto M, Taniguchi M, Yoshino S, Arai S, Sato K: S Phase-preferential Cre-recombination in mammalian cells revealed by HIV-TAT-PTD-mediated protein transduction. Journal of Biochemistry. 2008, 143 (1): 87-95.View ArticleGoogle Scholar
  18. Yu BD, Becker-Hapak M, Snyder EL, Vooijs M, Denicourt C, Dowdy SF: Distinct and nonoverlapping roles for pRB and cyclin D:cyclin-dependent kinases 4/6 activity in melanocyte survival. Proc Natl Acad Sci USA. 2003, 100 (25): 14881-14886.View ArticleGoogle Scholar
  19. Sauer B, Henderson N: Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc Natl Acad Sci USA. 1988, 85 (14): 5166-5170.View ArticleGoogle Scholar
  20. Melan MA, Sluder G: Redistribution and differential extraction of soluble proteins in permeabilized cultured cells. Implications for immunofluorescence microscopy. J Cell Sci. 1992, 101 (Pt 4): 731-743.Google Scholar
  21. Holm T, Johansson H, Lundberg P, Pooga M, Lindgren M, Langel U: Studying the uptake of cell-penetrating peptides. Nat Protoc. 2006, 1 (2): 1001-1005.View ArticleGoogle Scholar
  22. Lundberg M, Wikstrom S, Johansson M: Cell surface adherence and endocytosis of protein transduction domains. Mol Ther. 2003, 8 (1): 143-150.View ArticleGoogle Scholar
  23. Lundberg M, Johansson M: Positively charged DNA-binding proteins cause apparent cell membrane translocation. Biochem Biophys Res Commun. 2002, 291 (2): 367-371.View ArticleGoogle Scholar
  24. Lundberg M, Johansson M: Is VP22 nuclear homing an artifact?. Nat Biotechnol. 2001, 19 (8): 713-714.View ArticleGoogle Scholar
  25. Ross MF, Filipovska A, Smith RA, Gait MJ, Murphy MP: Cell-penetrating peptides do not cross mitochondrial membranes even when conjugated to a lipophilic cation: evidence against direct passage through phospholipid bilayers. Biochem J. 2004, 383 (Pt 3): 457-468.View ArticleGoogle Scholar
  26. Sauer B: Identification of cryptic lox sites in the yeast genome by selection for Cre-mediated chromosome translocations that confer multiple drug resistance. J Mol Biol. 1992, 223 (4): 911-928.View ArticleGoogle Scholar
  27. Thyagarajan B, Guimaraes MJ, Groth AC, Calos MP: Mammalian genomes contain active recombinase recognition sites. Gene. 2000, 244 (1–2): 47-54.View ArticleGoogle Scholar
  28. Loonstra A, Vooijs M, Beverloo HB, Allak BA, van Drunen E, Kanaar R, Berns A, Jonkers J: Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells. Proc Natl Acad Sci USA. 2001, 98 (16): 9209-9214.View ArticleGoogle Scholar
  29. Takayama K, Torashima T, Horiuchi H, Hirai H: Purkinje-cell-preferential transduction by lentiviral vectors with the murine stem cell virus promoter. Neurosci Lett. 2008, 443 (1): 7-11.View ArticleGoogle Scholar
  30. Will E, Klump H, Heffner N, Schwieger M, Schiedlmeier B, Ostertag W, Baum C, Stocking C: Unmodified Cre recombinase crosses the membrane. Nucleic Acids Res. 2002, 30 (12): e59-View ArticleGoogle Scholar
  31. Lin Q, Jo D, Gebre-Amlak KD, Ruley HE: Enhanced cell-permeant Cre protein for site-specific recombination in cultured cells. BMC Biotechnol. 2004, 4: 25-View ArticleGoogle Scholar
  32. Kellendonk C, Tronche F, Monaghan AP, Angrand PO, Stewart F, Schutz G: Regulation of Cre recombinase activity by the synthetic steroid RU 486. Nucleic Acids Res. 1996, 24 (8): 1404-1411.View ArticleGoogle Scholar
  33. Dupont E, Prochiantz A, Joliot A: Identification of a signal peptide for unconventional secretion. J Biol Chem. 2007, 282 (12): 8994-9000.View ArticleGoogle Scholar
  34. Gitton Y, Cohen-Tannoudji M, Wassef M: Role of thalamic axons in the expression of H-2Z1, a mouse somatosensory cortex specific marker. Cereb Cortex. 1999, 9 (6): 611-620.View ArticleGoogle Scholar
  35. Gitton Y, Cohen-Tannoudji M, Wassef M: Specification of somatosensory area identity in cortical explants. J Neurosci. 1999, 19 (12): 4889-4898.Google Scholar
  36. Dahmane N, Sanchez P, Gitton Y, Palma V, Sun T, Beyna M, Weiner H, Ruiz i Altaba A: The Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis. Development. 2001, 128 (24): 5201-5212.Google Scholar
  37. Joliot AH, Triller A, Volovitch M, Pernelle C, Prochiantz A: alpha-2,8-Polysialic acid is the neuronal surface receptor of antennapedia homeobox peptide. New Biol. 1991, 3 (11): 1121-1134.Google Scholar
  38. Bielle F, Griveau A, Narboux-Neme N, Vigneau S, Sigrist M, Arber S, Wassef M, Pierani A: Multiple origins of Cajal-Retzius cells at the borders of the developing pallium. Nat Neurosci. 2005, 8 (8): 1002-1012.View ArticleGoogle Scholar
  39. Raineteau O, Hugel S, Ozen I, Rietschin L, Sigrist M, Arber S, Gahwiler BH: Conditional labeling of newborn granule cells to visualize their integration into established circuits in hippocampal slice cultures. Mol Cell Neurosci. 2006, 32 (4): 344-355.View ArticleGoogle Scholar
  40. Cao G, Pei W, Ge H, Liang Q, Luo Y, Sharp FR, Lu A, Ran R, Graham SH, Chen J: In Vivo Delivery of a Bcl-xL Fusion Protein Containing the TAT Protein Transduction Domain Protects against Ischemic Brain Injury and Neuronal Apoptosis. J Neurosci. 2002, 22 (13): 5423-5431.Google Scholar
  41. Asoh S, Ohsawa I, Mori T, Katsura K, Hiraide T, Katayama Y, Kimura M, Ozaki D, Yamagata K, Ohta S: Protection against ischemic brain injury by protein therapeutics. Proc Natl Acad Sci USA. 2002, 99 (26): 17107-17112.View ArticleGoogle Scholar
  42. Silver DP, Livingston DM: Self-excising retroviral vectors encoding the Cre recombinase overcome Cre-mediated cellular toxicity. Mol Cell. 2001, 8 (1): 233-243.View ArticleGoogle Scholar
  43. Baba Y, Nakano M, Yamada Y, Saito I, Kanegae Y: Practical range of effective dose for Cre recombinase-expressing recombinant adenovirus without cell toxicity in mammalian cells. Microbiol Immunol. 2005, 49 (6): 559-570.View ArticleGoogle Scholar
  44. Rakic P: Specification of cerebral cortical areas. Science. 1988, 241 (4862): 170-176.View ArticleGoogle Scholar
  45. Bystron I, Blakemore C, Rakic P: Development of the human cerebral cortex: Boulder Committee revisited. Nature Review Neuroscience. 2008, 9 (2): 110-122.View ArticleGoogle Scholar
  46. Ruiz i Altaba A, Gitton Y, Dahmane N: Embryonic regionalization of the neocortex. Mech Dev. 2001, 107 (1–2): 3-11.View ArticleGoogle Scholar
  47. Cantor EJ, Chong S: Intein-mediated rapid purification of Cre recombinase. Protein Expr Purif. 2001, 22 (1): 135-140.View ArticleGoogle Scholar
  48. Soriano P: Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet. 1999, 21 (1): 70-71.View ArticleGoogle Scholar
  49. Srinivas S, Watanabe T, Lin CS, William CM, Tanabe Y, Jessell TM, Costantini F: Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev Biol. 2001, 1: 4-View ArticleGoogle Scholar
  50. Lobe CG, Koop KE, Kreppner W, Lomeli H, Gertsenstein M, Nagy A: Z/AP, a double reporter for cre-mediated recombination. Dev Biol. 1999, 208 (2): 281-292.View ArticleGoogle Scholar
  51. Hippenmeyer S, Vrieseling E, Sigrist M, Portmann T, Laengle C, Ladle DR, Arber S: A developmental switch in the response of DRG neurons to ETS transcription factor signaling. PLoS Biol. 2005, 3 (5): e159-View ArticleGoogle Scholar
  52. De Paola V, Arber S, Caroni P: AMPA receptors regulate dynamic equilibrium of presynaptic terminals in mature hippocampal networks. Nat Neurosci. 2003, 6 (5): 491-500.Google Scholar
  53. Benouaiche L, Gitton Y, Vincent C, Couly G, Levi G: Sonic hedgehog signalling from foregut endoderm patterns the avian nasal capsule. Development. 2008, 135 (13): 2221-2225.View ArticleGoogle Scholar


© Gitton et al; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.